Publicacións (21) Publicacións nas que participase algún/ha investigador/a

2024

  1. A multicentre ambispective observational study into the incidence and clinical management of aplastic anaemia in Spain (IMAS study)

    Annals of Hematology, Vol. 103, Núm. 3, pp. 705-713

  2. ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy

    Blood, Vol. 143, Núm. 18, pp. 1807-1815

  3. Activity and safety of eltrombopag in combination with cyclosporin A as first‑line treatment of adults with severe aplastic anaemia (SOAR): a phase 2, single-arm study

    The Lancet Haematology, Vol. 11, Núm. 3, pp. e206-e215

  4. Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI)

    American Journal of Hematology

  5. Bloqueo de las ramas cutáneas anteriores de los nervios intercostales para el control del dolor crónico por infiltración tumoral de carcinoma de mama metastásico

    MPJ Multidisciplinary Pain Journal, Núm. 1

  6. Cardiac events occurring after allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide. Study conducted on behalf of the GETH-TC

    Bone Marrow Transplantation

  7. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

    eClinicalMedicine, Vol. 71

  8. Diagnóstico por resonancia magnética de desgarros de la raíz posterior del menisco lateral

    MPG Journal, Vol. 4, Núm. 65

  9. Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?

    Annals of Hematology, Vol. 103, Núm. 8, pp. 2845-2851

  10. Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry

    Cancer, Vol. 130, Núm. 20, pp. 3436-3451

  11. Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice

    Blood, Vol. 144, Núm. 6, pp. 646-656

  12. Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis

    Leukemia

  13. Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience

    Annals of Hematology, Vol. 103, Núm. 2, pp. 451-461

  14. Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis

    HemaSphere

  15. Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry

    Haematologica, Vol. 109, Núm. 1, pp. 115-128

  16. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

    Blood, Vol. 143, Núm. 7, pp. 597-603

  17. Prognostic and survival factors in head and neck extra-nodal non-Hodgkin's lymphoma

    Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

  18. Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia

    Leukemia

  19. The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis

    American Journal of Hematology

  20. Transfusion medicine in our environment: Opportunities and threats

    Vox Sanguinis, Vol. 119, Núm. S1, pp. LD02-L01